Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL491561 | 0.77 | CYP1A2 (0.34) | KMT2ACYP1A2ALDH1A1 | |
| SCHEMBL4930532 | 0.68 | — | — | |
| SCHEMBL13696420 | 0.67 | GBA1 (0.47) | KMT2AGBA1SMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL318966 | 0.66 | — | — | |
| SCHEMBL13805996 | 0.65 | UHRF1 (0.46) | KMT2AGBA1SMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL2067842 | 0.65 | GBA1 (0.46) | KMT2AGBA1SMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL15953726 | 0.64 | TDP1 (0.37) | LMNACYP1A2MAPK1ALDH1A1 | |
| SCHEMBL596463 | 0.63 | — | — | |
| SCHEMBL3135272 | 0.63 | — | — | |
| SCHEMBL907735 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060270659-A1 | Pyrazolopyrimidines as CRF receptor antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7074797-B2 | Pyrazolopyrimidines as CRF receptor antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-07-11 | — | — | US | disclosed |
| US-6664261-B2 | Endocrine, psychiatric and neurologic disorders from hypersecretion of corticotropin-releasing factor | NEUROCRINE BIOSCIENCES, INC. | 2003-12-16 | — | — | US | disclosed |
| US-6469166-B2 | Thiophenopyrimidines | NEUROCRINE BIOSCIENCES, INC. | 2002-10-22 | — | — | US | disclosed |
| US-6255310-B1 | PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | NEUROCRINE BIOSCIENCES INC. | 2001-07-03 | — | — | US | disclosed |
| EP-0882051-A1 | THIOPHENOPYRIMIDINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997029110-A1 | THIOPHENOPYRIMIDINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270659-A1 | Pyrazolopyrimidines as CRF receptor antagonists | HTR5A, OPRL1, CRHR1 | KMT2A 3626/4885GBA1 4571/4885SMN1; SMN2 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.